PM Tracker

In the months since its far-reaching Class I recall began in June 2021, Philips has racked up a handful of others for many additional ventilators and breathing support devices that weren’t covered by the original safety notice.

Hospitals just weathered "some of the worst margins since the beginning of the COVID-19 pandemic" due to lower outpatient volumes and longer inpatient stays, Kaufman Hall wrote in its July report.

Alongside Teva, Amneal Pharmaceutical, Purdue subsidiary Rhodes Pharmaceuticals and Novartis’ soon-to-be-spun-off generics unit Sandoz have generic extended-released Adderall on back order, according to a recent supply update from the American Society of Health-System Pharmacists, which tracks drug shortages.

Follow along with the latest monkeypox news and insights from the Fierce Healthcare team.

Despite a $2.5 million check from a vaccine alliance earlier this summer, Codiak BioSciences is still struggling. The biotech is laying off around 30 employees and trimming its pipeline.

Nearly a decade after reeling in the first FDA nod allowing its deep brain stimulation technology to help treat major depressive disorder, BrainsWay has doubled back with another agency-cleared depression treatment.

Novartis is already suing a long list of generics producers that aim to bring copycats of the Swiss pharma’s popular heart failure drug Entresto to market. Now, the company itself has become target in a patent infringement lawsuit.

The hemophilia A market has a new date for the diary: Feb. 28. Officials at the FDA put the date on the agenda at Sanofi and Sobi by accepting the partners’ hemophilia A drug candidate efanesoctocog alfa for priority review.

InterWell Health completed a three-way merger with Fresenius Health Partners and Cricket Health to create a kidney care powerhouse on track to have $11 billion in costs under management by 2025. 

Fundraising can be a constant headache for many health tech startups—but not for Theranica. The company has managed to keep a steady stream of financing coming in and investors interested in its technology since its 2016 founding.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.